Click to Share
 

Naprx Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By NAPSRx
In a 13 to 3 vote, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S.
12399808
By NAPSRx
Valeant Pharmaceuticals has received approval from the U.S Food and Drug Administration (FDA)  for ONEXTON™ Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75% for the once-daily treatment of Acne vulgaris in patients 12 and older.
12399337
By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.
12398784
By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.
12396546
By NAPSRx
Pfizer and Merck KGaA have announced plans to enter into an agreement to jointly develop and commercialize the investigational anti-PD-L1 antibody MSB0010718C developed by Merck KGaA to treat multiple forms of cancer.
12395889
By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).
12392074
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s CYRAMZA® (ramucirumab) combined with paclitaxel (a type of chemotherapy) to treat individuals with a progressive form of  metastatic gastric (stomach) or gastroesophageal...
12391691
By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...
12390441
By NAPSRx
Abbvie has disclosed their Q3 report for 2014 and once again their breakthrough therapeutic treatment HUMIRA is leading the way in sales. Worldwide sales of HUMIRA increased 17.5 percent raking in $3.26 billion.
12389340
By NAPSRx
The Bayer Group has released their third quarter earnings for the 2014 financial year and the company beat analysts’ expectations posting a 13% rise in third-quarter net profit.
12388731
By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.
12388357
By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.
12387746
By NAPSRx
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.
12385255
By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.
By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.
By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.
By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.
By NAPSRx
Acorda Therapeutics announced on September 24, 2014, their plans to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.
By NAPSRx
Eli Lilly is a global healthcare leader committed to creating high-quality medicines that meet real needs.
By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

All Press Releases

By NAPSRx
In a 13 to 3 vote, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S.
By NAPSRx
Janssen Biotech a division of Johnson & Johnson ( J & J) will pay $241 million for Vedanta Bioscience’s mix of bacteria from the Clostridia subspecies that could potentially treat Crohn’s disease and ulcerative colitis.
By NAPSRx
Shire will acquire NPS Pharmaceuticals for $46.00 per share in cash amounting to approximately $5.2 billion. The acquisition will give Shire access to NPS Pharma’s gastrointestinal (GI) disorders portfolio and rare disease pipeline.
By NAPSRx
Incyte Corporation has received approval for Jakafi® (ruxolitinib), the first and only FDA-approved oral medication for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
12399808
By NAPSRx
Valeant Pharmaceuticals has received approval from the U.S Food and Drug Administration (FDA)  for ONEXTON™ Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75% for the once-daily treatment of Acne vulgaris in patients 12 and older.
12399337
By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.
12398784
By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.
12396546
By NAPSRx
Pfizer and Merck KGaA have announced plans to enter into an agreement to jointly develop and commercialize the investigational anti-PD-L1 antibody MSB0010718C developed by Merck KGaA to treat multiple forms of cancer.
12395889
By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).
By NAPSRx
AstraZeneca and Amgen’s investigational psoriasis treatment brodalumab posted successful results from the AMAGINE-3TM multi-arm Phase III trial.
By NAPSRx
The U.S. Food and Drug Administration (FDA) has accepted for review, Amgen’s Biologics License Application (BLA) for evolocumab to treat high cholesterol.
12392074
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s CYRAMZA® (ramucirumab) combined with paclitaxel (a type of chemotherapy) to treat individuals with a progressive form of  metastatic gastric (stomach) or gastroesophageal...
12391691
By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...
12390441
By NAPSRx
Abbvie has disclosed their Q3 report for 2014 and once again their breakthrough therapeutic treatment HUMIRA is leading the way in sales. Worldwide sales of HUMIRA increased 17.5 percent raking in $3.26 billion.
By NAPSRx
Abilify is found to be the preferred brand for the treatment of Schizophrenia according to surveyed U.S. Psychiatrists and Payers
12389340
By NAPSRx
The Bayer Group has released their third quarter earnings for the 2014 financial year and the company beat analysts’ expectations posting a 13% rise in third-quarter net profit.
12388731
By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.
12388357
By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.
12387746
By NAPSRx
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.
By NAPSRx
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.
By NAPSRx
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...
12385255
By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.
By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.
By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.
By NAPSRx
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...
By NAPSRx
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.
By NAPSRx
Novartis and Bristol-Myers Squibb will join forces on a clinical collaboration which involves evaluating the safety, tolerability and preliminary efficacy of Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational...
By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.
By NAPSRx
Acorda Therapeutics announced on September 24, 2014, their plans to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.
By NAPSRx
A pharmaceutical sales rep is one of the most coveted positions one can achieve in the sales industry.  Companies are looking for qualified pharmaceutical sales executives to manage their accounts across the United States.

Page:
Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share